Get In Touch

Cervical Cancer Diagnostic Tests Market: Snapshot

Advances in screening methods in cervical cytology along with increasing implementation of cervical screening programs, particularly in developing economies, are key to high growth momentum in the cervical cancer diagnostics tests market. Cervical cancer is associated with high mortality rate in such economies. Growing numbers of people who became newly infected with HIV in the past couple years have triggered the need for cervical cancer diagnostic tests. According to 2018 update by the WHO, cervical cancer is the fourth most frequent cancer in women, with a majority of mortality found in low- and middle-income countries in recent years. Efforts of governments in increasing access to screening programs are broadening the outlook of the market.

The global cervical cancer diagnostic tests market is expected to garner a healthy 6.10% CAGR during 2014 - 2020. The market stood at US$5.9 bn in 2013 and is projected to reach worth of US$8.9 bn by 2020-end.

Demand for Pap Tests Widespread for Detecting Potentially Precancerous Cells

The report segments the cancer diagnostic tests market on the basis of type of test and region. Major types of tests in cervical cancer are Pap smear tests, human papilloma virus (HPV) testing, colopscopy, and endocervical curettage (ECC) procedure, and an others segment. The others segment include loop electrosurgical excision procedure (LEEP) and cone biopsy. Of these, HPV testing and Pap tests have been popularly used in the diagnosis of cervical cancer for entirely different reasons. Pap tests have become popular in detecting potentially precancerous and cancerous processes, notably before more sensitive screening methods are used in cervical cancer patients.

The HPV segment is anticipate to expand at 8% CAGR between 2014 and 2020. The Pap smear tests segment is projected to clock a CAGR of more than 6% during 2014 – 2020. To a great deal, opportunities in the segment have thrived due to increased focus on early detection of cervical cancer. The tests are used in early detection of glandular cell abnormalities.

Improvement in diagnostic technology for detecting pre-cancerous lesions catalyzed demand for both types of tests in the cervical cancer diagnostic tests market. Growing incidences of cervical cancer and growing awareness about the disease will likely advance the market potential of colopscopy, ECC, and LEEP tests for diagnosing cervical cancer tests.

Increased Penetration of Screening Programs Cemented Growth in North America

The various regional markets for cervical cancer diagnostic tests are North America, Asia Pacific, Rest of the World, and Europe. Of all the regions, North America held the majority of share in 2013. Growing participation of regional populations in screening programs over the past few years had helped the regional market attain a prominent share. This has led to decreasing incidence of cervical cancer mortality. Further, substantial efforts have been made by public health systems to update guidelines for diagnosing cervical cancer.

Meanwhile, Asia Pacific is presenting large lucrative avenue. The demand for cervical cancer diagnostic tests has risen on the back of the growing initiatives by governments to reduce the heal burden and mortality rate due to cancer. The high unmet need for screening technologies in numerous countries is catalyzing the overall growth of this regional market.

Cervical cancer is a medical condition in which cells present in the lining of the cervix - gradually develop into pre-cancerous mass of cells that ultimately turn into cancerous tumors. Two major types of cervical cancers that are typically screened and diagnosed in women include adenocarcinoma and squamous cell carcinoma. At the same time, it has been observed that approximately 90% cases of cervical cancers are squamous cell carcinoma. Virtually, almost all the cases of cervical cancer cases are due to specific types of human papillomavirus and there are more than 100 different types of HPV virus present, of which nearly 40 are sexually transmitted. Among these, about 15 different types HPV viruses are considered as high-risk type or cancer causing. Today, cervical cancer is recognized to be one of the most common types of cancers affecting U.S. women and ranks 14th in frequency. Worldwide, cervical cancer is the third most common cancer among women and the second most frequent cause of cancer-related death, accounting for almost 300,000 deaths annually.
This research report provides a detailed analysis of the global cervical cancer diagnostic tests market and helps in understanding the various driving factors for the growth of the market. The market overview section analyzes market dynamics and trends such as drivers, restraints and opportunities that influence the current nature and future status of the market. The executive summary provides detailed insights about the report and the market in general. It also contains a market snapshot, which provides a glimpse into the present scenario of the global cervical cancer diagnostic tests market. Impact factors such as market attractiveness analysis and Porter’s five forces analysis have also been explained in the market overview section of the report in order to deliver a thorough analysis of the overall competitive scenario of the global cervical cancer diagnostic tests market. 
The global cervical cancer diagnostic tests market is segmented based on types of tests performed for the diagnosis of cancer patients. Based on the test types, the market is segmented into Pap smear tests, HPV testing, colposcopy, endocervical curettage procedure and others, which comprise cone biopsy and Loop Electrosurgical Excision Procedure (LEEP). Market size estimates and forecasts for the period 2012 to 2020 have been provided for each of the segments mentioned above in terms of USD million, considering 2013 as the base year for calculating market forecast and 2012 as the historical year. The CAGR (%) of each market segment for the forecast period 2014 to 2020 has also been provided along with market size estimations.
Geographically, the global cervical cancer diagnostic tests market has been segmented into four major regional markets: North America, Europe, Asia Pacific and Rest of World (RoW). The market size estimations and forecasts for the period 2012 to 2020 have been provided for each of these regions at a segment level, in terms of USD million along with the CAGR for the forecast period 2014 to 2020. This study further offers market recommendations for the global cervical cancer diagnostic tests market. These include factors that may play a critical role in enhancing or boosting the market in the near future, as well as steps that need to be considered to ensure success for manufacturers. 
The report concludes with the company profiles section and includes key information about the major players who are actively participating in this market. The company profiles included in the report are framed in terms of company overview, financial overview, business strategies, recent developments and product portfolio. Key players profiled in this report include Abbott Laboratories, Becton, Dickinson and Company, Hologic, Inc., F. Hoffmann-La Roche Ltd., Quest Diagnostics, Inc., QIAGEN N.V., Femasys, Inc., Zilico Ltd., Guided Therapeutics, Inc., OncoHealth Corp.,

Custom Market Research Services

TMR offers custom market research services that help clients to get information on their business scenario required where syndicated solutions are not enough.


Cervical Cancer Diagnostic Tests Market

Buy Now